CRISPR Therapeutics 2023: CASGEVY approved in 5 countries; Q4 net income $89.3M

CRISPR Therapeutics AG

2023-FY EPS reported -$1.94 revenue$371,206,000

CASGEVY (exa-cel) approved in U.S., EU, Great Britain, Bahrain, KSA for SCD and TDT; ~35,000 patients in U.S. and Europe.
Q4 net income $89.3M vs net loss $110.6M in Q4 2022; cash $1.7B at year-end, pro-forma >$2.1B after $200M milestone and $280M offering.
Clinical trials ongoing for next-gen CAR T (CTX112, CTX131) and in vivo programs (CTX310, CTX320); CTX112 trial in SLE planned H1 2024.
R&D expenses $95.1M in Q4 (down from $103.6M), G&A $16.5M (down from $21.2M); collaboration expense net $20M.
Vertex paid $170M in 2023 milestones; eligible for additional $160M milestones plus royalties.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 21, 2024, CRISPR Therapeutics AG announced its financial results for the year ended December 31, 2023 and other business highlights.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported financial results for the fourth quarter ended December 31, 2023.

Period: the fourth quarter ended December 31, 2023
Result: reported results

Exact text from the filing

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

View on SEC.gov

Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0000950170-24-017568

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.